Alipogene tiparvovec

Active ingredient description

Alipogene tiparvovec contains the human lipoprotein lipase (LPL) gene variant LPLS447X in a vector. The human LPL gene variant LPLS447X in an adeno-associated virus serotype 1 (AAV1) vector intended to target the muscle. Alipogene tiparvovec is injected as a one-time series into the muscle of the lower extremities where it is taken up by myocytes.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Alipogene tiparvovec
C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents
Discover more medicines within C10AX10

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Summary of Product Characteristics (SPC)

External identifiers

CAS Substance: 929881-05-0
DrugBank Drug: DB13521
KEGG Drug: D10843
PubChem Compound: 838
UNII Identifier: 20OK4AFR4Y


Alipogene tiparvovec is an active ingredient of these brands:

Estonia (EE)

Lithuania (LT)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.